Immunoassay CDMO sales will grow through 2036, led by manufacturing and production at 52.8% of the services segment in 2026. The market was valued at USD 11.20 billion in 2025 and is expected to be worth USD 28.61 billion by 2036, creating an incremental opportunity of USD 16.41 billion.